Summary & Overview
CPT 93505: Endomyocardial Biopsy for Heart Transplant Rejection Evaluation
CPT code 93505 represents an endomyocardial biopsy performed to obtain myocardial tissue for assessment of heart transplant rejection. This procedure has national clinical importance for post-transplant surveillance and definitive diagnosis of rejection, guiding immunosuppression management and influencing patient outcomes. It is commonly performed in hospital-based settings, including catheterization laboratories and specialized cardiac procedural suites.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage considerations and variations, typical sites of service, and commonly reported utilization patterns.
Readers will find benchmarks for utilization and coverage trends, a concise clinical context explaining the role of endomyocardial biopsy in transplant care, and a summary of policy and billing considerations that affect reimbursement and service reporting. Where input data is incomplete, the publication notes "Data not available in the input." The focus is national in scope and intended for clinical program managers, billing professionals, and policy analysts seeking a focused reference on CPT code 93505.
Billing Code Overview
CPT code 93505 describes an endomyocardial biopsy procedure in which the provider obtains tissue samples from the innermost layer of the heart muscle to evaluate for cardiac allograft rejection after heart transplantation. This service is a diagnostic tissue sampling procedure performed to detect cellular or antibody-mediated damage to the transplanted heart.
-
Service type: Diagnostic endomyocardial biopsy
-
Typical site of service: Hospital inpatient or outpatient cardiac catheterization laboratory or specialized cardiac procedural suite
Clinical & Coding Specifications
Clinical Context
A 56-year-old male, six months post orthotopic heart transplantation, is scheduled for a routine surveillance endomyocardial biopsy to evaluate for acute cellular or antibody-mediated rejection. The patient arrives to the cardiac catheterization laboratory after pre-procedure evaluation including review of recent immunosuppression levels, vital signs, and coagulation status. Under conscious sedation or monitored anesthesia care, the interventional cardiologist obtains central venous access (typically via the right internal jugular vein) and advances a bioptome into the right ventricle under fluoroscopic guidance. Multiple small tissue samples are taken from the endomyocardium — the innermost layer of the heart muscle — and submitted in appropriate media for histopathology and immunohistochemistry. Hemostasis is achieved at the access site, the patient is monitored in recovery for arrhythmia or vascular complications, and specimens are sent to pathology for grading of rejection. Typical site of service is the hospital outpatient department or cardiac catheterization laboratory. Service type: diagnostic invasive cardiac biopsy/sampling for transplant rejection surveillance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the physician interpretation component separate from the technical component |